Comparison
GHRP-2 vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Healing
CAS no.
158861-67-7
no data
Molecular weight
817.93 g/mol
888 g/mol
Half-life
0.5 h
no data
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2Ac-LKKTETQMechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human trial
Animal model
Studies
4
3
of which in humans
4
0
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
1
2